EDIT - エディタス・メディシン （Editas Medicine Inc.） エディタス・メディシンEDITのチャート
EDITの企業情報
| symbol | EDIT |
|---|---|
| 会社名 | Editas Medicine Inc （エディタス・メディシン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エディタス・メディシン（Editas Medicine Inc.）はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復（CRISPR）技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9（Cas9）またはPrevotellaおよびFrancisella 1（Cpf1）由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸（RNA）複合体を使用し、特定のデオキシリボ核酸（DNA）配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10（LCA10）のゲノム編集治療薬を開発している。 エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子のゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。 As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. |
| 本社所在地 | 11 Hurley Street Cambridge MA 02141 USA |
| 代表者氏名 | James C. Mullen ジェームスC.ミューレン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-401-9000 |
| 設立年月日 | 41518 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 112人 |
| url | www.editasmedicine.com |
| nasdaq_url | https://www.nasdaq.com/symbol/edit |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -131.47100 |
| 終値（lastsale） | 27.88 |
| 時価総額（marketcap） | 1329196954.72 |
| 時価総額 | 時価総額（百万ドル） 1323.476 |
| 売上高 | 売上高（百万ドル） 21.24800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 112.34 |
| 当期純利益 | 当期純利益（百万ドル） -132.45000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense). |
EDITのテクニカル分析
EDITのニュース
Is Editas Medicine Inc.’s (NASDAQ:EDIT) Stock On The Decline? 2023/02/07 14:30:00 Stocks Register
The trading price of Editas Medicine Inc. (NASDAQ:EDIT) closed lower on Monday, February 06, closing at $11.12, -1.24% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $11.005 and $11.4802. In examining the 52-week price action we see that the stock hit a 52-week … Is Editas Medicine Inc.’s (NASDAQ:EDIT) Stock On The Decline? Read More »
Why Editas Medicine''s Shares Jumped This Week 2023/02/03 17:10:58 The Motley Fool
The gene-editing biotech''s shares have had a strong two-week run.
Is Editas Medicine Stock a Buy Now? 2023/02/03 11:15:00 The Motley Fool
Layoffs and a thin clinical-stage pipeline aren''t very encouraging.
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later 2023/02/02 17:58:23 InvestorPlace
CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR, to try to improve human health. Using CRISPR, scientists can slice into DNA, altering it and reducing the negative impact of a variety of maladies. CRISPR-based medicines and therapies are currently being tested as treatments for cancer, neurodegenerative diseases, and other illnesses. CRISPR has come a long way in a short time. An initial paper documenting the phenomenon was published in 2011, and the authors received a Nobel Prize for their work in 2020. Meanwhile, the FDA has started to approve drugs based on the technology. That said, some challenges remain when it comes to using CRISPR. It is expensive and technically challenging to develop certain kinds of therapies based on gene editing. In addition, side effects have been observed, such as those caused by off-target responses, Regardless, money keeps flowing into the gene editing space, and these three CRISPR stocks are worthy of investors’ attention going forward.
Why Editas Medicine Stock Charged Higher in January 2023/02/02 16:33:09 The Motley Fool
The genome-editing company''s shares spiked following a definitive agreement with Shoreline Biosciences last month.
Editas Medicine Stock: Q3 Update; 2 Clinical Catalysts To Watch (NASDAQ:EDIT) 2022/11/04 11:45:18 Seeking Alpha
I believe EDIT will be unlikely to catch up with peers with much more advanced clinical studies. See here for upcoming catalysts and key risks facing EDIT.
Editas Medicine Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag 2022/11/04 10:14:17 Simply Wall St
Editas Medicine ( NASDAQ:EDIT ) Third Quarter 2022 Results Key Financial Results Revenue: US$42.0k (down 99% from 3Q…
Editas Medicine rises 7% on Q3 earnings beat (NASDAQ:EDIT) 2022/11/02 15:43:01 Seeking Alpha
Editas Medicine (EDIT) is trading 7% higher after the company posted better-than expected Q3 GAAP EPS. The company recorded collaboration and other research and development revenues…
Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript 2022/11/02 14:50:29 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Q3 2022 Earnings Conference Call November 02, 2022 08:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief…
A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments 2022/11/02 14:42:54 STAT News
Other CRISPR companies command multibillion-dollar valuations, but Editas trades below its IPO price following upheaval and clinical delay.
Editas Medicine, Inc. (EDIT) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference Call Transcript 2022/09/12 18:53:03 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022, 10:30 AM ET Company Participants Gilmore O’Neill - President and…
Editas Medicine, Inc. (EDIT) Presents at 2022 Wells Fargo Healthcare Conference (Transcript) 2022/09/07 21:57:06 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) 2022 Wells Fargo Healthcare Conference September 07, 2022 01:55 PM ET Company Participants Gilmore O''Neill - Chief Executive Officer Mark Shearman…
Have you been able to find a good deal on Editas Medicine Inc.’s shares? 2022/09/07 11:24:00 US Post News
Editas Medicine Inc. (NASDAQ:EDIT) marked $14.30 per share on Tuesday, down from a previous closing price of $14.83. While Editas Medicine Inc. has underperformed by -3.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT fell by -79.05%, with highs and lows ranging from $72.50 to […]
Editas Medicine Inc. (NASDAQ:EDIT) Could Actually Go To $80.00 In 12 Months 2022/09/02 14:00:00 Marketing Sentinel
In last trading session, Editas Medicine Inc. (NASDAQ:EDIT) saw 1.31 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $15.42 trading at $0.72 or 4.90% at ring of the bell on the day assigns it a market valuation of $1.16B. That closing price of EDIT’s stock is … Editas Medicine Inc. (NASDAQ:EDIT) Could Actually Go To $80.00 In 12 Months Read More »